- Home
- BST vs HROW Comparison
BST vs HROW Comparison
Compare BST & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- HROW
- Stock Information
- Founded
- BST 2014
- HROW 1998
- Country
- BST United States
- HROW United States
- Employees
- BST N/A
- HROW N/A
- Industry
- BST Finance Companies
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- BST Finance
- HROW Health Care
- Exchange
- BST Nasdaq
- HROW Nasdaq
- Market Cap
- BST 1.5B
- HROW 1.4B
- IPO Year
- BST N/A
- HROW N/A
- Fundamental
- Price
- BST $42.20
- HROW $38.68
- Analyst Decision
- BST
- HROW Strong Buy
- Analyst Count
- BST 0
- HROW 7
- Target Price
- BST N/A
- HROW $68.50
- AVG Volume (30 Days)
- BST 92.9K
- HROW 856.1K
- Earning Date
- BST 01-01-0001
- HROW 11-12-2025
- Dividend Yield
- BST 7.21%
- HROW N/A
- EPS Growth
- BST N/A
- HROW N/A
- EPS
- BST N/A
- HROW N/A
- Revenue
- BST N/A
- HROW $227,661,000.00
- Revenue This Year
- BST N/A
- HROW $43.92
- Revenue Next Year
- BST N/A
- HROW $41.32
- P/E Ratio
- BST N/A
- HROW N/A
- Revenue Growth
- BST N/A
- HROW 47.69
- 52 Week Low
- BST $27.87
- HROW $20.85
- 52 Week High
- BST $42.78
- HROW $55.75
- Technical
- Relative Strength Index (RSI)
- BST 62.99
- HROW 43.27
- Support Level
- BST $41.00
- HROW $38.32
- Resistance Level
- BST $41.80
- HROW $42.31
- Average True Range (ATR)
- BST 0.65
- HROW 2.44
- MACD
- BST -0.06
- HROW -0.36
- Stochastic Oscillator
- BST 69.94
- HROW 32.87
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.